Lupin launches Rocuronium Bromide injection in US
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin's Nagpur facility in India
Lupin enters into BTA with Lupin Manufacturing Solutions
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
India has the highest prevalence of diabetes globally, with an estimated 77 million people living with the condition and an expected 134 million cases by 2045
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Pirfenidone Capsules had estimated annual sales of USD 95 million in the US
Subscribe To Our Newsletter & Stay Updated